Therapeutic impact of Citrus paradisi peel extract on muscular trichinellosis: an in vivo study.

Abstract

Trichinellosis is a parasitic zoonosis caused by a nematode parasite of the Trichinella (T.) genus. It poses significant public health issues due to limited effective and safe treatment options, especially for the muscle-encysted larval stage. Citrus paradisi (C. paradisi), with its high content of flavonoids and polyphenols, has been recorded to possess anti-parasitic properties and numerous therapeutic applications. The present work aimed to assess the efficacy of C. paradisi extract peel extract as a therapeutic agent, either alone or combined with albendazole (ABZ), against T. spiralis in experimentally infected mice. Sixty-six lab-bred Swiss albino mice were divided into control and treatment groups, then received either ABZ, C. paradisi extract, or a combination of both during the enteral, migratory, and encapsulation phases of infection. Parasitological, histopathological, and immunohistochemical examinations were performed to evaluate the efficacy of the treatments. All treated groups displayed a highly significant difference (p < 0.001) in larval counts compared to the positive control group, with the combination therapy group having the highest efficacy and the lowest mean count value during different treatment regimens. In addition, treated groups showed improved muscle integrity compared to the positive control group. Moreover, the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) showed the highest expression reduction in the combination therapy group. These findings highlight the potential of C. paradisi as a complementary therapy to albendazole for treating trichinellosis through muscle larva reduction and mitigation of inflammation.